Skip to main content

Psoriatic arthritis

    Rheumatology Round-Up with Drs. Kavanaugh & Cush

    The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

    Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies

    Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.

    Mid-Meeting Recap: Psoriatic Arthritis

    On Saturday, November 7th, Drs. Cush and Kavanaugh discuss psoriatic arthritis reports from ACR 2020 with Dr. Eric Ruderman and Dr. Robert Chao.

    Enthesitis in PsA: Dr. Robert Chao

    Dr. Robert Chao reviews abstracts #1853, #1552, #1543 and #2021 presented at the 2020 ACR annual meeting. 

     

     

    RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,
    3 years 3 months ago

    Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

    Who has more comorbidities? Dr. Janet Pope

    Dr. Janet Pope reviews abstract #1466 presented at the 2020 ACR annual meeting. Who has more comorbidities: OA, Gout, RA or PsA? 

    RT @doctorRBC: Deucravacitinib TYK2i for PsA
    Phase2b 16wk, Double-blind, Placebo, RCT
    ⬆️ACR20/50/70 response vs. PBO
    3 years 3 months ago
    Deucravacitinib TYK2i for PsA Phase2b 16wk, Double-blind, Placebo, RCT ⬆️ACR20/50/70 response vs. PBO ⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO *⃣No serious AE @RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
    Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial o
    3 years 3 months ago
    Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
    RT @doctorRBC: Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you r
    3 years 3 months ago
    Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you routinely use MRI to monitor disease activity in your PsA patients? @RheumNow #ACR20